Overview

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Status:
Completed

Trial end date:
2021-05-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.

Phase:

Phase 2

Details

Lead Sponsor:

InflaRx GmbH

Collaborators:

IQVIA
Iqvia Pty Ltd

Treatments:

Vilobelimab